Short Interest in NextCure, Inc. (NASDAQ:NXTC) Expands By 29.6%

NextCure, Inc. (NASDAQ:NXTC) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totaling 26,706 shares, a growth of 29.6% from the November 30th total of 20,613 shares. Based on an average trading volume of 45,355 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.1% of the shares of the company are sold short. Approximately 1.1% of the shares of the company are sold short. Based on an average trading volume of 45,355 shares, the days-to-cover ratio is presently 0.6 days.

Hedge Funds Weigh In On NextCure

An institutional investor recently raised its position in NextCure stock. Cable Car Capital LP increased its position in shares of NextCure, Inc. (NASDAQ:NXTC) by 13.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 758,141 shares of the company’s stock after buying an additional 88,040 shares during the period. Cable Car Capital LP owned 28.29% of NextCure worth $349,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Stock Up 5.8%

Shares of NextCure stock opened at $13.98 on Wednesday. NextCure has a 12-month low of $2.69 and a 12-month high of $15.74. The company has a market capitalization of $49.07 million, a price-to-earnings ratio of -0.58 and a beta of 1.54. The firm’s 50-day moving average price is $11.27 and its two-hundred day moving average price is $7.62.

NextCure (NASDAQ:NXTC) last issued its earnings results on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.06) by $0.84. On average, sell-side analysts expect that NextCure will post -1.87 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on NXTC shares. LADENBURG THALM/SH SH raised NextCure from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Friday, November 7th. Wall Street Zen upgraded shares of NextCure to a “hold” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NextCure in a research report on Friday, October 31st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.